Cumberland Pharmaceuticals Inc.: updates and filings

CPIXNASDAQHealthcare · Pharmaceutical Preparations

Price

$5.21

November 16, 2026Market cap $78M

What Ploutos Investor adds for Cumberland Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 25% since Aug 7, 2026, when the 10-Q these figures come from was filed ($7.80 then, $5.88 on Nov 13, 2026). The figures date from before that move.10-Q
  • The reported profit is far larger than a business usually earns on its market value, which usually means one-off or accounting gains. We leave out the P/E and the earnings yield.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 84 daysAround Feb 8, 2027 · for Q4 2026

last Nov 10, 2026next Feb 8, 2027

A rough estimate from when it has reported before, which has varied. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 9, 2026 latest annualNov 13, 2026 latest quarterly
  • Nov 13, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 10, 2026Results of operations
    Form8-K
  • Oct 26, 2026Regulation FD disclosure, other material events
    Form8-K
  • Oct 23, 2026Other material events
    Form8-K
  • Sep 11, 2026Shareholder vote (amendment)
    Form8-K/A
  • Aug 28, 2026Regulation FD disclosure
    Form8-K
  • Aug 7, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 4, 2026Results of operations
    Form8-K
  • Jul 13, 2026Other material events
    Form8-K
  • Jul 1, 2026Material agreement entered, material agreement ended, acquisition or disposal of assets, officer or director change, other material events
    Form8-K
  • Jun 25, 2026Shareholder vote
    Form8-K
  • May 26, 2026Merger meeting proxy statement
    FormDEFM14A
  • May 15, 2026Filing
    FormPREM14A
  • May 8, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 5, 2026Results of operations
    Form8-K
  • Apr 24, 2026Shareholder vote
    Form8-K
  • Apr 23, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 23, 2026Material agreement entered, Regulation FD disclosure, other material events
    Form8-K
  • Mar 12, 2026Annual report to shareholders
    FormARS
  • Mar 9, 2026Additional annual meeting material
    FormDEFA14A
  • Mar 9, 2026Annual meeting proxy statement
    FormDEF 14A
  • Mar 9, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Mar 3, 2026Results of operations
    Form8-K
  • Feb 9, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Feb 4, 2026Other material events
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 2, 2002.

The full analysis

What do Cumberland Pharmaceuticals's filings show?

The filings are where every one of Cumberland Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.